Hypothyroidism – Medxy AI

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery

By MedXY 07/04/2026

Hypothyroidism increases the incidence of CABG and is linked to higher risks of postoperative complications, heart failure, stroke, and major adverse cardiovascular events, highlighting the importance of preoperative thyroid function optimization.

Diabetes & Endocrinology news

Levothyroxine Dosing and the Risk of Suboptimal Thyroid Control: Insights from a Large Real-World Longitudinal Study

By MedXY 07/03/2026

This real-world study demonstrates a dose-dependent increase in suboptimal thyroid hormone control among adults treated with levothyroxine, emphasizing the need for enhanced TSH monitoring in patients on higher doses.

Diabetes & Endocrinology news

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism

By MedXY 06/05/2026

A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Long-Term Risk of Hypothyroidism After Thyroid Abnormalities Identified in Pregnancy

By MedXY 06/04/2026

Thyroid abnormalities found during pregnancy, especially when subclinical hypothyroidism and TPO antibodies coexist, can signal a much higher long-term risk of overt hypothyroidism, supporting ongoing thyroid follow-up after delivery.

Diabetes & Endocrinology Internal Medicine news

Breaking the Fasting Mandate: Is It Time to Re-evaluate Levothyroxine Administration?

By MedXY 03/18/2026

A randomized clinical trial demonstrates that a 15% dose increase allows levothyroxine to be taken with breakfast without compromising TSH stability, significantly improving patient preference and well-being.

Diabetes & Endocrinology news

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

By MedXY 03/12/2026

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for long-term management during the menopause transition.